Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiovascular Disease
Pre-IND meeting held with FDA for platelet aggregation inhibitor
September 5th, 2004
Inspire Pharmaceuticals, Inc., (ISPH) announced that a pre-Investigational New Drug (IND) meeting was held on July 29 with the U.S. Food and Drug Administration for INS50589 Cardiovascular. This product candidate is being investigated as an intravenously administered reversible platelet aggregation inhibitor that may be useful in preventing platelet activation and protecting platelet function during cardiopulmonary bypass procedures, thereby potentially reducing surgical and post-surgical complications. Mark F. Newman, MD, Merel H. Harmel professor and chairman, Department of Anesthesiology at Duke University Medical Center, commented, "There is...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
